Abstract
Statins display numerous effects independent of their well described lipid-lowering effect that may be of potential benefit in preventing vascular injury and ischemic vascular events. These effects may both prevent and improve vessel wall abnormalities. We review the current literature to provide support that statins may have a modifying effect on the vasculopathy, fibrosis and immune dysregulation observed in systemic sclerosis.
Keywords: Systemic sclerosis, scleroderma, statins, vasculopathy, tissue fibrosis
Letters in Drug Design & Discovery
Title: Inhibition of Geranyl-Geranyl Prenylation by Statins: A Novel Model of Disease Modification of Systemic Sclerosis
Volume: 3 Issue: 3
Author(s): Chris T. Derk
Affiliation:
Keywords: Systemic sclerosis, scleroderma, statins, vasculopathy, tissue fibrosis
Abstract: Statins display numerous effects independent of their well described lipid-lowering effect that may be of potential benefit in preventing vascular injury and ischemic vascular events. These effects may both prevent and improve vessel wall abnormalities. We review the current literature to provide support that statins may have a modifying effect on the vasculopathy, fibrosis and immune dysregulation observed in systemic sclerosis.
Export Options
About this article
Cite this article as:
Derk T. Chris, Inhibition of Geranyl-Geranyl Prenylation by Statins: A Novel Model of Disease Modification of Systemic Sclerosis, Letters in Drug Design & Discovery 2006; 3 (3) . https://dx.doi.org/10.2174/157018006776286998
DOI https://dx.doi.org/10.2174/157018006776286998 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Characteristics of Animal Models for Scleroderma
Current Rheumatology Reviews DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Randomised Trials of Graft Versus Host Disease Prophylaxis in Haemopoietic Stem Cell Transplantation
Reviews on Recent Clinical Trials The Association of Collagenase with Human Diseases and its Therapeutic Potential in Overcoming them
Current Biotechnology Tachykinins: Role in Human Gastrointestinal Tract Physiology and Pathology
Current Drug Targets Mycophenolate Mofetil for the Treatment of Systemic Sclerosis
Letters in Drug Design & Discovery Gender Disparity in Pediatric Diseases
Current Molecular Medicine Current Approaches to Prevention of Contrast Induced Acute Kidney Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot topic: Interstitial Lung Disease with Connective Tissue Diseases (Guest Editor: Eric Matteson)]
Current Rheumatology Reviews Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry Collagen-Binding Integrins as Pharmaceutical Targets
Current Pharmaceutical Design Systemic Autoimmune Manifestations: When Should Underlying Thyroid Autoimmunity be Considered?
Current Rheumatology Reviews Synthesis and Comparison of Antimalarial Activity of Febrifugine Derivatives Including Halofuginone
Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Recombinant Protein Based Therapeutics for IPF
Inflammation & Allergy - Drug Targets (Discontinued) Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Substance P in Rheumatic Diseases
Current Rheumatology Reviews Editorial from Editor-in-Chief
Current Rheumatology Reviews